TNFα inhibitors restrict T cell activation and cycling via Notch-1 signalling in inflammatory bowel disease

Gut

Volumn 61, Issue 7, 2012, Pages 1016-1027

  Werner, Lael ^a   Berndt, Uta ^a   Paclik, Daniela ^a   Danese, Silvio ^b   Schirbel, Anja ^a   Sturm, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; ENTERITIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY; ULCERATIVE COLITIS; UPREGULATION;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL CYCLE CHECKPOINTS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; RECEPTOR, NOTCH1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861573386     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301267     Document Type: Article

References (61)

1. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102:2058-69. (Pubitemid 47301524)
2. Zenewicz LA, Antov A, Flavell RA. CD4 T-cell differentiation and inflammatory bowel disease. Trends Mol Med 2009;15:199-207.
3. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009;361:2066-78.
4. Sturm A, Leite AZ, Danese S, et al. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 2004;53:1624-31. (Pubitemid 39434106)
5. Sturm A, de Souza HS, Fiocchi C. Mucosal T cell proliferation and apoptosis in inflammatory bowel disease. Curr Drug Targets 2008;9:381-7. (Pubitemid 352025212)
6. Peyrin-Biroulet L, Deltenre P, de SN, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644-53. (Pubitemid 351783447)
7. Mudter J, Neurath MF. Apoptosis of T cells and the control of inflammatory bowel disease: therapeutic implications. Gut 2007;56:293-303.
8. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79.
9. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005;128:376-92. (Pubitemid 40431090)
10. Meusch U, Rossol M, Baerwald C, et al. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. Arthritis Rheum 2009;60:2612-21.
11. Zolkiewska A. ADAM proteases: ligand processing and modulation of the Notch pathway. Cell Mol Life Sci 2008;65:2056-68.
12. Delwig A, Rand MD. Kuz and TACE can activate Notch independent of ligand. Cell Mol Life Sci 2008;65:2232-43.
13. Osborne BA, Minter LM. Notch signalling during peripheral T-cell activation and differentiation. Nat Rev Immunol 2007;7:64-75. (Pubitemid 46020828)
14. Yuan JS, Kousis PC, Suliman S, et al. Functions of notch signaling in the immune system: consensus and controversies. Annu Rev Immunol 2010;28:343-65.
15. Dahan S, Rabinowitz KM, Martin AP, et al. Notch-1 signaling regulates intestinal epithelial barrier function, through interaction with CD4+ T cells, in mice and humans. Gastroenterology 2011;140:550-9.
16. Yao J, Qian C. Over-activated Notch-1 protects gastric carcinoma BGC-823 cells from TNFalpha-induced apoptosis. Dig Liver Dis 2009;41:867-74.
17. Quillard T, Devalliere J, Chatelais M, et al. Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin. PLoS One 2009;4:e8244.
18. Fernandez L, Rodriguez S, Huang H, et al. Tumor necrosis factor-alpha and endothelial cells modulate Notch signaling in the bone marrow microenvironment during inflammation. Exp Hematol 2008;36:545-58.
19. Nakazawa M, Ishii H, Aono H, et al. Role of Notch-1 intracellular domain in activation of rheumatoid synoviocytes. Arthritis Rheum 2001;44:1545-54. (Pubitemid 32642217)
20. Ando K, Kanazawa S, Tetsuka T, et al. Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts. Oncogene 2003;22:7796-803. (Pubitemid 37485538)
21. Gersemann M, Becker S, Kubler I, et al. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009;77:84-94.
22. Dotan I, Werner L, Vigodman S, et al. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm Bowel Dis 2010;16:583-92.
23. Paclik D, Danese S, Berndt U, et al. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One 2008;3:e2629.
24. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-9. (Pubitemid 29295252)
25. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005;21:251-8. (Pubitemid 40278362)
26. Poznic M. Retinoblastoma protein: a central processing unit. J Biosci 2009;34:305-12.
27. Olsen T, Cui G, Goll R, et al. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol 2009;44:727-35.
28. Buch MH, Reece RJ, Quinn MA, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008;47:1469-75.
29. Okamoto R, Tsuchiya K, Nemoto Y, et al. Requirement of Notch activation during regeneration of the intestinal epithelia. Am J Physiol Gastrointest Liver Physiol 2009;296:G23-35.
30. Radtke F, Wilson A, Mancini SJ, et al. Notch regulation of lymphocyte development and function. Nat Immunol 2004;5:247-53. (Pubitemid 38332121)
31. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003;194:237-55. (Pubitemid 36176887)
32. Zhao G, Liu Z, Ilagan MX, et al. Gamma-secretase composed of PS1/Pen2/Aph1a can cleave notch and amyloid precursor protein in the absence of nicastrin. J Neurosci 2010;30:1648-56.
33. Doerfler P, Shearman MS, Perlmutter RM. Presenilin-dependent gamma-secretase activity modulates thymocyte development. Proc Natl Acad Sci U S A 2001;98:9312-17. (Pubitemid 32743913)
34. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002;2:364-71. (Pubitemid 37328759)
35. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alphaexpressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008;58:1248-57. (Pubitemid 351705913)
36. Ringheanu M, Daum F, Markowitz J, et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004;10:801-10. (Pubitemid 39545226)
37. Eissner G, Kirchner S, Lindner H, et al. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J Immunol 2000;164:6193-8. (Pubitemid 30408797)
38. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001;15:212-22. (Pubitemid 34587646)
39. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006;176:2617-24. (Pubitemid 43201714)
40. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295-302. (Pubitemid 39120115)
41. Wagner U, Pierer M, Wahle M, et al. Ex vivo homeostatic proliferation of CD4+ T cells in rheumatoid arthritis is dysregulated and driven by membrane-anchored TNFalpha. J Immunol 2004;173:2825-33. (Pubitemid 39063144)
42. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25: 5220-7. (Pubitemid 44299080)
43. Kimura K, Hirano M, Kobayashi R, et al. Phosphorylation and activation of 13S condensin by Cdc2 in vitro. Science 1998;282:487-90. (Pubitemid 28483678)
44. Kramer A, Mailand N, Lukas C, et al. Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 2004;6:884-91. (Pubitemid 39207253)
45. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009;458:1127-30.
46. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005;65:3980-5. (Pubitemid 40775632)
47. Cox LS. Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. J Pathol 1997;183:134-40. (Pubitemid 27436015)
48. Bettelli E, Korn T, Oukka M, et al. Induction and effector functions of T(H)17 cells. Nature 2008;453:1051-7. (Pubitemid 351871737)
49. Ehebauer M, Hayward P, Arias AM. Notch, a universal arbiter of cell fate decisions. Science 2006;314:1414-15. (Pubitemid 44871939)
50. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
51. Carlesso N, Aster JC, Sklar J, et al. Notch1-induced delay of human hematopoietic progenitor cell differentiation is associated with altered cell cycle kinetics. Blood 1999;93:838-48. (Pubitemid 29067848)
52. Cereseto A, Tsai S. Jagged2 induces cell cycling in confluent fibroblasts susceptible to density-dependent inhibition of cell division. J Cell Physiol 2000;185:425-31.
53. Morimura T, Goitsuka R, Zhang Y, et al. Cell cycle arrest and apoptosis induced by Notch1 in B cells. J Biol Chem 2000;275:36523-31. (Pubitemid 32002049)
54. Schroeder T, Just U. mNotch1 signaling reduces proliferation of myeloid progenitor cells by altering cell-cycle kinetics. Exp Hematol 2000;28:1206-13.
55. Jehn BM, Bielke W, Pear WS, et al. Cutting edge: protective effects of notch-1 on TCR-induced apoptosis. J Immunol 1999;162:635-8. (Pubitemid 29035380)
56. Shelly LL, Fuchs C, Miele L. Notch-1 inhibits apoptosis in murine erythroleukemia cells and is necessary for differentiation induced by hybrid polar compounds. J Cell Biochem 1999;73:164-75. (Pubitemid 29160184)
57. Ohishi K, Varnum-Finney B, Flowers D, et al. Monocytes express high amounts of Notch and undergo cytokine specific apoptosis following interaction with the Notch ligand, Delta-1. Blood 2000;95:2847-54. (Pubitemid 30235894)
58. Sturm A, Itoh J, Jacobberger JW, et al. p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. J Clin Invest 2002;109:1481-92. (Pubitemid 34596174)
59. King IN, Kathiriya IS, Murakami M, et al. Hrt and Hes negatively regulate Notch signaling through interactions with RBP-Jkappa. Biochem Biophys Res Commun 2006;345:446-52.
60. Blobel CP. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell 1997;90:589-92. (Pubitemid 27357951)
61. Osipo C, Golde TE, Osborne BA, et al. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest 2008;88:11-17.